

SETTLEMENTS OF ACCOUNTS

From 1st April 2022
to 31th March 2023

Concord Biotech Japan K.K.



Atsushi SATO, President

OHUMURA Tax Account Office

2029-2 Ichihama, Numazu, Shizuoka, JAPAN

〒410-0312

静岡県沼津市原2029-2

大村税理士事務所

税理士 大村 勇次

TEL 0559(67)6318



BALANCE SHEETS

As at 31th March 2023

CONCORD BIOTECH JAPAN K.K.

JPY

Assets		Liabilities	
<u>Current assets</u>	410,197,593	<u>Current liabilities</u>	190,852,378
Cash and deposit	70,572,305	Account payable-trade	184,800,000
Promissory notes [Receivable]	140,140,000	Short-term borrowing	453,374
Allowance for doubtful accounts	-1,401,400	Accounts payable	95,157
Product inventory	200,480,991	Accrued consumption tax	4,221,200
Prepaid expenses	405,697	Deposits payable	1,282,647
		<u>Long-term liabilities</u>	84,501,180
		Long-term borrowings	84,501,180
<u>Fixed assets</u>	4,750,057	Liabilities total:	275,353,558
Fixed assets	314,277	<u>Net Equity</u>	
Bulidings and other facilities	209,925	<u>Stockholders equity</u>	139,594,092
Machinery and equipment	104,352	Capital	20,000,000
<u>Investment and other assets</u>	4,435,780	Accumulated earnings	119,594,092
Capital	10,000	Other accumulated earnings	119,594,092
Guarantee deposits	4,425,780	Brought down accumulated earnings	119,594,092
		(Net gain of current period)	56,110,409
		Net equity total	139,594,092
Asset total:	414,947,650	Liabilities and net equity total:	414,947,650

 

INCOME STATEMENT

From 1st April 2022 to 31th March 2023

CONCORD BIOTECH JAPAN K.K.

JPY

<u>Net sales</u>		
Amount of sales	779,800,000	
Overseas sales	280,000,000	
Net sales total		1,059,800,000
<u>Cost of sales</u>		
Opening [Initial] Inventory	200,458,512	
Imported Purchases	646,800,000	
Import charges	796,459	
Import inspection	15,400	
Export charges	480,230	
Domestic Purchases	436,333	
Overseas Purchases	277,200,000	
Total	1,126,186,934	
Closing [End] Inventory	200,480,991	
Cost of sales		925,705,943
Gross profit		134,094,057
<u>Selling, general & administrative expenses</u>		
Total of selling, general & administrative expenses		79,061,492
Sales gain		55,032,565
<u>Non-operating gain</u>		
Interest received	1,396	
Divident received	250	
Miscellaneous income	8,648	
Non-operating gain total		10,294
<u>Non-operating loss</u>		
Interest paid	14,804	
Discount expense	274,246	
Non-operating loss total		289,050
Ordinary gain		54,753,809
<u>Non-operating loss</u>		
Reversal of allowance for doubtful accounts	1,356,600	
Extoraordinary gain total		1,356,600
Gain of income before income tax		56,110,409
Net gain		56,110,409

Handwritten signature



Selling, General & Administrative Expenses

From 1st April 2022 to 31st March 2023

CONCORD BIOTECH JAPAN K.K.

JPY

Payments for directors, A.Sato and Utako Sato	22,410,000	
Salary	25,782,750	
Contribution to Health Insurance & Pension Fund	2,688,203	
Welfare expense	40,708	
Transportation	84,152	
Advertising expenses	1,156,440	
Meeting expenses	20,100	
Traveling expenses	1,173,017	
Communications	294,446	
Office Supplies [like Printing & Stationery etc.]	1,295,909	
Office maintenance expense	1,892,501	
Utilities	242,602	
Books and subscription expenses	26,000	
Membership expenses	3,637	
Bank charges	859,259	
Drug regulatory expenses	388,340	
Payments to Consultants	614,000	
Depreciation expenses	67,172	
Office rent	5,370,792	
Taxes, Stamp Duty on Promissory Notes and Other	13,250,064	
Provision of allowance for doubtful accounts	1,401,400	
Total:		79,061,492

 